Answers are grounded in this paper and cite their sources.
Retrospective study evaluates MSI-high colon cancer outcomes in community oncology, highlighting implications for treatment.
e15585 Background: Microsatellite instability–high (MSI-H) colon cancer represents a distinct molecular subset with prognostic and therapeutic implications particularly in the era of immunotherapy. However, real-world data from community oncology settings in India remains limited. Methods: This retrospective study evaluated MSI-H colon cancer patients from March 2018 to May 2025 at Western India community oncology centers. PFS and OS were analyzed using Kaplan-Meier. Results: A total of 1100 colon cancer patients were evaluated out of which 358 underwent MSI testing & 66/358 (18.43%) were MSI-H. The median age of the MSI-H cohort was 66 years (IQR, 43.5–72), with M:F ratio of 1.7:1; most patients had an ECOG PS of 0–1 (87.8%)& stage distribution was: Stage I -3.0%, Stage II- 40.9%, Stage III -48.5%,Stage IV- 7.6%. MSI testing was performed at baseline in 80.3% & at progression in 19.7%, predominantly by IHC (86.3%), followed by NGS (10.6%) and PCR (3%). Loss of expression was most frequently observed for hMLH-1 (47%) followed by hPMS-2 (45.5%), hMSH-2 (18.2%) and hMSH-6 (16.7%). In 31.8% (n = 21), expression status was unknown, with variable instability detected across microsatellite markers NR-21 (n = 2), NR-24 (n = 2), BAT-25 (n = 2), BAT-26 (n = 2), and MONO-27 (n = 1). MSI-H incidence was most common in adenocarcinoma (95%) most commonly involved the ascending (n = 34) and descending colon (n = 11) with a predominance of right-sided over left-sided disease (54.5% vs 42.4%).PD-L1 status was available in 7.6% (n = 5), with positivity in 4/5 and TMB-high ( > 10muts) in n = 1. Common co-mutation included KRAS (n = 2). First line therapy was mainly surgery (n = 61), chemotherapy (n = 35) and targeted therapy (n = 4). Immunotherapy was administered in combination or as single agent to 9.3% (n = 6) with distribution: Pembrolizumab, nivolumab and dostarlimab in n = 2 each with 60% ORR. Among first line recipients, best responses included complete response in 39.1%, partial response in 14.1%, and stable disease in 10.9%. For MSI tested patients, the median follow-up was 19.9 months (95% CI 17.4-22.4) and Median OS (mOS) was not reached in either the MSI-stable or MSI-H groups with 23.9%(n = 70) and 6.1% (n = 4)events reported respectively (NA; 95% CI, NA–NA) (p = 0.001). Median PFS was 25.9 months (95% CI, 15.96–35.8) in MSI-stable cohort vs 71.9 months (95% CI, 0.0–168.02) in the MSI-H cohort (p = 0.006). Conclusions: This real-world analysis from Western India identifies MSI-H colon cancer as a biologically distinct entity with right-sided predominance and superior survival outcomes; however, underutilization of MSI testing and immunotherapy underscores the need for systematic MSI assessment to facilitate timely, biomarker-driven treatment in community oncology settings.
No takes yet. Share an insight, caveat, or question.
Maniar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: